VTGN - ビスタジェン・セラピュ―ティクス (VistaGen Therapeutics Inc.)

VTGNのニュース

   Maxim Group Downgrades VistaGen Therapeutics to Hold  2022/07/26 11:48:02 Investing.com
https://www.investing.com/news/pro/maxim-group-downgrades-vistagen-therapeutics-to-hold-432SI-2853985
   Why Is Pagaya Technologies (PGY) Stock Soaring 94% Today?  2022/07/22 17:06:55 InvestorPlace
Source: shutterstock.com/Peshkova Pagaya Technologies (NASDAQ: PGY ) stock is rocketing higher on Friday despite a lack of news from the financial tech company today. While there’s no news today, Pagaya Technologies did announce a prospectus earlier this week that saw its shares surge in value. Since then, the stock continued to hold its value until it shot even higher today. That prospectus has the company considering offering 673 million shares and warrants for another 46.1 million. News of this prospectus resulted in an over 100% boost to the stock on Wednesday. While it’s been a couple of days since then, it’s possible that investors are still piling into PGY stock because of that news. We could also see retail and day traders taking stakes in the company considering its relativly low price point. What we do know is that PGY stock is experiencing incredibly heavy trading today. As of this writing, more than 43 million shares of the stock have changed hands. That’s well above its daily average trading volume of 986.9 million shares. 7 Best Reddit Stocks to Buy Now But what exactly does Pagaya Technologies do?
   VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data  2022/07/22 16:30:55 InvestorPlace
Source: Bukhta Yurii / Shutterstock.com VistaGen Therapeutics (NASDAQ: VTGN ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study . That clinical trial covers PH94B as a treatment for anxiety in adults with social anxiety disorder. The bad news is that PH94B failed to meet the primary endpoint of the clinical trial. That means it failed to cause a significant change from baseline on the Subjective Units of Distress Scale when compared to a placebo. Despite the poor results from the Phase 3 clinical trial, VistaGen Therapeutics isn’t giving up on PH94B just yet. The company intends to continue the ongoing PALISADE-2 Phase 3 trial and Phase 2 trial in adjustment disorder with anxiety. 7 Best Reddit Stocks to Buy Now Shawn Singh, CEO of VistaGen Therapeutics, said the following about the clinical trial results. “The demand for new treatment options for anxiety disorders is large and growing. While the results of PALISADE-1 are not consistent with prior positive results from Phase 2 trials of PH94B in social anxiety disorder, we remain committed to transforming the treatment landscape for those living with anxiety, depression, and other central nervous system disorders.” It’s worth pointing out that PH94B is one of three drug candidates in the company’s pipeline.
   Baird Downgrades VistaGen Therapeutics to Neutral  2022/07/22 16:25:01 Investing.com
https://www.investing.com/news/pro/baird-downgrades-vistagen-therapeutics-to-neutral-432SI-2852142
   Jefferies Downgrades VistaGen Therapeutics to Hold  2022/07/22 15:24:02 Investing.com
https://www.investing.com/news/pro/jefferies-downgrades-vistagen-therapeutics-to-hold-432SI-2852107
   VistaGen to Participate in Upcoming June Investor Conferences  2022/05/27 12:30:00 Kwhen Finance
   VistaGen to Participate in Upcoming June Investor Conferences  2022/05/27 12:30:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in the following upcoming investor conferences in June. Management will be available for one-on-one meetings during these confere
   VistaGen Therapeutics Inc. (NASDAQ: VTGN) Is Under Pressure Due To Weak Fundamental Momentum.  2022/05/25 14:00:00 Marketing Sentinel
In the last trading session, 1.01 million VistaGen Therapeutics Inc. (NASDAQ:VTGN) shares changed hands as the company’s beta touched 0.99. With the company’s per share price at $1.02 changed hands at -$0.02 or -1.92% during last session, the market valuation stood at $222.66M. VTGN’s last price was a discount, traded about -248.04% off its 52-week … VistaGen Therapeutics Inc. (NASDAQ: VTGN) Is Under Pressure Due To Weak Fundamental Momentum. Read More »
   7 Cheap Biotech Stocks to Buy Now  2022/05/19 22:00:38 InvestorPlace
This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ): Clinical-stage biotech with truckloads of cash to take its novel immune tolerance platform past the finish line. Bluebird Bio ( BLUE ): Speculative biotech with a colossal growth runway if the FDA gives its gene therapies the green light. Vistagen Therapeutics ( VTGN ): Unique portfolio of therapeutics which target the nervous system in an industry set for tremendous growth ahead. BioNano Genomics Inc ( BNGO ): This meme stock could develop a long-term recurring revenue-generating machine with its genome image editing tool. Verastem ( VSTM ): This startup develops novel cancer treatments with the goal of delivering the best-in-class RAS pathway product. BioCryst Pharmaceuticals ( BCRX ): Biotech with a robust rare disease drug portfolio and strong liquidity. Source: Mongkolchon Akesin / Shutterstock.com Amidst immense market volatility, investors favor value-oriented sectors to minimize risk.
   VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety  2022/05/05 14:56:42 Seeking Alpha
VistaGen Therapeutics (VTGN) on Thursday said the FDA agreed that the company''s nasal spray PH94B for the acute treatment of social anxiety disorder did not show any abuse potential
   Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $330,000.00  2021/12/04 09:12:41 Dakota Financial News
Equities research analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to announce $330,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics reported sales of $310,000.00 during the same quarter last year, which would suggest a positive year over year []
   Renaissance Technologies LLC Buys Shares of 102,641 VistaGen Therapeutics, Inc. (NASDAQ:VTGN)  2021/11/26 09:36:45 Transcript Daily
Renaissance Technologies LLC bought a new position in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) in the 2nd quarter, Holdings Channel reports. The fund bought 102,641 shares of the companys stock, valued at approximately $323,000. A number of other institutional investors have also recently made changes to their positions in VTGN. Xponance Inc. bought a new []
   State Street Corp Purchases Shares of 3,059,610 VistaGen Therapeutics, Inc. (NASDAQ:VTGN)  2021/11/25 10:24:41 Dakota Financial News
State Street Corp acquired a new stake in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,059,610 shares of the companys stock, valued at approximately $9,638,000. State Street Corp owned 1.59% of VistaGen Therapeutics as of []
   Nuveen Asset Management LLC Invests $2.16 Million in VistaGen Therapeutics, Inc. (NASDAQ:VTGN)  2021/11/24 09:34:41 Dakota Financial News
Nuveen Asset Management LLC acquired a new position in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 686,380 shares of the companys stock, valued at approximately $2,163,000. A number of other institutional investors have also modified their []
   $330,000.00 in Sales Expected for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) This Quarter  2021/11/23 01:42:41 Dakota Financial News
Equities analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report sales of $330,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics posted sales of $310,000.00 during the same quarter last year, which suggests a positive year over year growth []

calendar